293 related articles for article (PubMed ID: 23617697)
1. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and anti-hepatocellular carcinoma activity of novel O
Zou Y; Yan C; Liu JC; Huang ZJ; Xu JY; Zhou JP; Zhang HB; Zhang YH
Chin J Nat Med; 2017 Dec; 15(12):928-937. PubMed ID: 29329650
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O
Kang F; Ai Y; Zhang Y; Huang Z
Eur J Med Chem; 2018 Apr; 149():269-280. PubMed ID: 29501947
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
7. O
Li Q; Zou P; Sun J; Chen L
Eur J Med Chem; 2018 Jan; 143():732-744. PubMed ID: 29220794
[TBL] [Abstract][Full Text] [Related]
8. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
9. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
10. NG, a novel PABA/NO-based oleanolic acid derivative, induces human hepatoma cell apoptosis via a ROS/MAPK-dependent mitochondrial pathway.
Liu L; Fu J; Li T; Cui R; Ling J; Yu X; Ji H; Zhang Y
Eur J Pharmacol; 2012 Sep; 691(1-3):61-8. PubMed ID: 22824464
[TBL] [Abstract][Full Text] [Related]
11. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs.
Fang L; Wang M; Gou S; Liu X; Zhang H; Cao F
J Med Chem; 2014 Feb; 57(3):1116-20. PubMed ID: 24422538
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma.
Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F
Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895
[TBL] [Abstract][Full Text] [Related]
13. Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents.
Huang Z; Fu J; Liu L; Sun Y; Lai Y; Ji H; Knaus EE; Tian J; Zhang Y
Org Biomol Chem; 2012 May; 10(19):3882-91. PubMed ID: 22473516
[TBL] [Abstract][Full Text] [Related]
14. Glutathione S-Transferase π-Activatable O
Huang Z; Wu J; Zou Y; Yuan H; Zhang Y; Fei Y; Bhardwaj A; Kaur J; Knaus EE; Zhang Y
J Med Chem; 2018 Mar; 61(5):1833-1844. PubMed ID: 29420887
[TBL] [Abstract][Full Text] [Related]
15. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
[TBL] [Abstract][Full Text] [Related]
16. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
17. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
18. Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.
Hutchens S; Manevich Y; He L; Tew KD; Townsend DM
Invest New Drugs; 2011 Oct; 29(5):719-29. PubMed ID: 20232108
[TBL] [Abstract][Full Text] [Related]
19. NG as a novel nitric oxide donor induces apoptosis by increasing reactive oxygen species and inhibiting mitochondrial function in MGC803 cells.
Liu L; Li T; Tan J; Fu J; Guo Q; Ji H; Zhang Y
Int Immunopharmacol; 2014 Nov; 23(1):27-36. PubMed ID: 25135879
[TBL] [Abstract][Full Text] [Related]
20. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
